Quarterly report pursuant to Section 13 or 15(d)

Collaborations, Licensing Agreements and Other Agreements - Additional Information (Details)

v3.23.1
Collaborations, Licensing Agreements and Other Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2023
May 31, 2020
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2023
May 31, 2023
Feb. 28, 2023
Jan. 01, 2023
Oct. 07, 2022
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Research and development expense     $ 12,435,000 $ 9,170,000            
Accrued and Other Current Liabilities                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Expenses     400,000              
License and Service [Member]                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Upfront Payment     1,200,000              
Subsequent Event [Member]                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Upfront Payment             $ 500      
License Agreement                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Obligation to be paid     $ 2,000,000              
Payment term     3 years              
Payment commencement date     2018-08              
License maintenance fee   $ 33,000 $ 10,000              
Total milestone payments     21,000,000              
Amounts due to agreement     0              
Sponsored Research Agreements                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Obligation to be paid     12,560,000              
Master Translational Research Services Agreement                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Research and development expense     1,511,000 $ 635,000            
Oxford Biomedica                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Obligation to be paid         $ 4,000,000          
Research and development expense         $ 1,100,000          
Nanjing IASO Biotherapeutics Co., Ltd. [Member]                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Total milestone payments     1,000,000              
Upfront Payment     $ 162,000,000             $ 2,500,000
Autolus Holdings [Member]                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Upfront Payment               $ 800 $ 1,200,000  
Autolus Holdings [Member] | Maximum [Member]                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Total milestone payments $ 15,000,000                  
Autolus Holdings [Member] | Maximum [Member] | License and Service [Member]                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Total milestone payments $ 12,000,000                  
Autolus Holdings [Member] | Subsequent Event [Member]                    
Collaborations, Licensing Agreements And Other Agreements [Line Items]                    
Upfront Payment           $ 100